Probenecid competes with meropenem for active tubular secretion and thus, inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of Meronem dosed without probenecid are adequate, the co-administration of probenecid with Meronem is not recommended.
The potential effect of Meronem on the protein-binding of other drugs or metabolism has not been studied. The protein-binding of Meronem is low (approximately 2%), and therefore, no interactions with other compounds based on displacement from plasma proteins would be expected.
Meronem may reduce serum valproic acid levels. Subtherapeutic levels may be reached in some patients.
Meronem has been administered concomitantly with other medications without adverse pharmacological interactions. However, no specific data regarding potential drug interactions are available.
Incompatibilities: Meronem should not be mixed or added to other drugs. Meronem is compatible with the following infusion fluids: 0.9% sodium chloride solution; 5 or 10% glucose solution; 5% glucose solution with 0.02% sodium bicarbonate; 5% glucose solution and 0.9% sodium chloride; 5% glucose with 0.225% sodium chloride solution; 5% glucose with 0.15% potassium chloride solution; mannitol 2.5 or 10% solution.